RxDoctor Payments Data

Mikhail Chilingaryan, MD

Internal Medicine · Pittsburgh, PANPI 1356581201

Payments from drug & device makers

$10,235in general payments, 2019–2025

Across 435 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$848
  • GSK$795
  • Lilly USA, LLC$793
  • Ardelyx, Inc.$593
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,15099%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,235 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$239,967
Medicare patients
458
Services billed
2,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate870$1,193,878
FarxigaDapagliflozin Propanediol980$584,430
Diclofenac Potassium325$505,044
Metformin Er GastricMetformin Hcl439$474,753
CreonLipase/Protease/Amylase341$439,011
OzempicSemaglutide427$406,126
LinzessLinaclotide687$375,910
JardianceEmpagliflozin539$333,944
Diflorasone Diacetate427$274,445
TrulicityDulaglutide263$264,032
VascepaIcosapent Ethyl756$255,307
DapagliflozinDapagliflozin Propanediol436$226,749
Fenofibrate686$213,387
Diclofenac Sodium659$196,690
JanuviaSitagliptin Phosphate316$179,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$1,524$871,6441,115 claims
AstraZenecaFarxiga$1,503$584,430980 claims
Novo NordiskOzempic, Rybelsus$584$462,771486 claims
Lilly USA, LLCTrulicity, Mounjaro$793$389,619382 claims
Boehringer IngelheimJardiance$396$333,944539 claims
MerckJanuvia, Janumet$89$280,873500 claims
GSKTrelegy Ellipta$795$153,151239 claims
PfizerEliquis, Nurtec Odt$86$128,306182 claims
Astellas Pharma US IncMyrbetriq$129$123,355270 claims
BayerKerendia$543$66,82096 claims
Aimmune Therapeutics, Inc.Zenpep$70$47,16742 claims
NovartisEntresto$359$42,26864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →